Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Italy / NCT07817524
Active, not recruiting Observational

Clinical Outcome of Coronary Artery Bypass Graft Surgery Versus Percutaneous Coronary Intervention in Patients With Severe Left Ventricular Disfunction (CROWN)

NCT07817524 · tracked via the Priya Life Science Italy tracker
Sponsor
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase
Observational
Started
2025-08-01
Last updated
2026-09-14

Condition(s) studied

Coronary Artery DiseaseLeft Ventricular Cardiac Dysfunction

Study summary

The objective of this study is to evaluate the best treatment strategy in patients with critical coronary artery disease and severe left ventricular dysfunction.

In details, main goal of the study is to compare the clinical outcomes of patients with critical coronary artery disease and severe left ventricular dysfunction undergoing surgical coronary artery bypass grafting with those of patients treated by percutaneous coronary intervention.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Age \>= 18 years old; * Written informed consent; * Indication to CABG surgery (both "on-pump" and "off-pump") or to PCI; * Preoperative EF ≤35%. Exclusion Criteria: * Inability to give written informed consent; * Emergency surgery; * Combined cardiac surgical procedures; * Previous cardiac surgery.

Primary outcome measure(s)

  • All-cause mortality — through study completion, an average of 1 year
    Number of patients who died for any cause after CABG or PCI

Trial sites (1)

FacilityCityRegionStatus
Fondazione Policlinico Universitario A Gemelli IRCCS Roma Italy

More Fondazione Policlinico Universitario Agostino Gemelli IRCCS trials in Italy

Spatial Radiogenomics of Ovarian Cancer Recruiting
Cardiovascular Health in Adult Patients With Cancer Exposed to Cardiotoxic Therapies Recruiting
Echocardiographic Characterization of Cardiac Amyloidosis Recruiting
ECT STUDY High-grade or Initially Invasive Vulva - GinOnc-ECT Study Active, not recruiting
Youth Suicide Risk Factors, Reduction of Suicide Risk Factor in Youth People Recruiting

Other trials for the same condition

SPAGO: Sirolimus Paclitaxel Angiographic Gain Objective Recruiting
Intracoronary Optical Coherence Tomography Guidance Vs. Angiography Only Guidance for Treatment of Coronary In-stent Restenosis Recruiting
Precise Procedural and PCI Plan (P4) Active, not recruiting
DynamX Bioadaptor Global Post-Market Registry: Clinical Trial of the Elixir Medical DynamX Coronary Bioadaptor System Recruiting
Randomization of Single vs Multiple Arterial Grafts Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07817524 on ClinicalTrials.gov ↗ ← All trials in Italy